Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3) who have relapsed or have metastasis following chemotherapy.
Checked against the public recordLast updated Jan 26, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Karyopharm Therapeutics Inc
- Interventions being studied
- Drug: Selinexor (KPT-330)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * 18 years of age or older * confirmed SCC of the head and neck, lung, or esophagus * 1 to 2 prior therapies * measurable disease at screening and documented progression within the past 6 weeks Exclusion Criteria: * patients requiring total parenteral nutrition * unstable cardiovascular function * substantially impaired gastrointestinal function * Symptomatic brain metastases * another malignancy within 3 years except adequately treated in situ carcinoma of any type, basal or non-melanomatous skin cancer
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Colorado Cancer CenterAurora, Colorado
- Lee Moffitt Cancer Center and Research InstituteTampa, Florida
- Northwestern UniversityEvanston, Illinois
- Tufts Medical CenterBoston, Massachusetts
- Dana-Farber Cancer Institute / Harvard UniversityBoston, Massachusetts
- Metrowest Medical CenterFramingham, Massachusetts
- Karmanos Cancer InstituteDetroit, Michigan
- Washington University School of Medicine / Washington University in St. LouisSt Louis, Missouri
- Hackensack University Medical CenterHackensack, New Jersey
- Icahn School of Medicine at Mount SinaiNew York, New York
- Herbert Irving Comprehensive Cancer Center / Columbia UniversityNew York, New York
- Gabrail Cancer CenterCanton, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 26, 2023. Always confirm current availability with the study team.